| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject inhibitor capable of suppressing turnover sthenia of skin such as acanthosis, parakeratosis, abnormality of skin lipid metabolism, etc., caused by ultraviolet rays, etc., and normalizing skin keratinization by including a sphingosine. SOLUTION: This inhibitor contains a sphingosine (e.g. a compound of the formula or the like) being a physiologically active component existing in skin. The amount of the sphingosine formulated is, in the case of using the inhibitor as an emulsion-based external preparation for skin, 0.001-5 wt.%, and in the case of using an oily external preparation for skin comprising a liquid hydrocarbon such as squalane or the like, 0.01-10 wt.%. The sphingosine is obtained by extracting sphingolipid, etc., from a proper tissue (e.g. bovine brain or the like), hydrolyzing and extracting the hydrolyzate with an organic solvent.
|
